Betancor, DianaOlaguibel, José MaríaRodrigo Muñoz, José ManuelArismendi, EbymarBarranco, PilarBarroso, BlancaBobolea, IrinaCárdaba, BlancaCruz, María JesúsCurto, ElenaPozo, Victoria delGonzález Barcala, Francisco JavierMartínez Rivera, CarlosMullol i Miret, JoaquimMuñoz, XavierPicado Vallés, CésarPlaza, VicenteQuirce, SantiagoRial Prado, Manuel JorgeSoto, LorenaValero, AntonioValverde Monge, MarcelaSastre, Joaquín2023-06-212023-06-212022-08-202045-7022https://hdl.handle.net/2445/199606Asthma is a heterogeneous respiratory disease that encompasses different inflammatory and functional endophenotypes. Many non-invasive biomarkers has been investigated to its pathobiology. Heany et al proposed a clinical algorithm that classifies severe asthmatic patients into likely-eosinophilic phenotypes, based on accessible biomarkers: PBE, current treatment, FeNO, presence of nasal polyps (NP) and age of onset.We assessed the concordance between the algorithm proposed by Heany et al. with sputum examination, the gold standard, in 145 asthmatic patients of the MEGA cohort with varying grades of severity.No correlation was found between both classifications 0.025 (CI = 0.013-0.037). Moreover, no relationship was found between sputum eosinophilia and peripheral blood eosinophilia count in the total studied population.In conclusion, our results suggest that grouping the biomarkers proposed by Heany et al. are insufficient to diagnose eosinophilic phenotypes in asthmatic patients. Sputum analysis remains the gold standard to assess airway inflammation.© 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.6 p.application/pdfengcc by (c) Betancor, Diana et al, 2022http://creativecommons.org/licenses/by/3.0/es/AsmaMarcadors bioquímicsMatemàtica aplicadaAsthmaBiochemical markersApplied mathematicsinfo:eu-repo/semantics/article2023-06-20info:eu-repo/semantics/openAccess932909436000018